Evidence map›Paper›PMID 32219612›Full record

ArticleDigestive diseases and sciences2021

Favorable Survival with Non-curative Treatments for Patients with Early-Stage Hepatocellular Carcinoma After Liver Transplant Denial.

Andreas Zori, Faith Villanueva, Diana Hatamleh, Media Ismael, Justin Forde, Manoela Mota, Lindsey Johnson, Roniel Cabrera

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Andreas ZoriDivision of Gastroenterology, Hepatology and Nutrition, University of Florida, 1600 SW Archer Rd, Gainesville, FL, USA.
Faith VillanuevaDepartment of Medicine, University of Florida, 1600 SW Archer Rd, Gainesville, FL, USA. faith.villanueva@medicine.ufl.edu.
Diana HatamlehDepartment of Medicine, University of Florida, 1600 SW Archer Rd, Gainesville, FL, USA.
Media IsmaelDepartment of Medicine, University of Florida, 1600 SW Archer Rd, Gainesville, FL, USA.
Justin FordeDepartment of Medicine, University of Florida, 1600 SW Archer Rd, Gainesville, FL, USA.
Manoela MotaDivision of Gastroenterology, Hepatology and Nutrition, University of Florida, 1600 SW Archer Rd, Gainesville, FL, USA.
Lindsey JohnsonDepartment of Medicine, University of Florida, 1600 SW Archer Rd, Gainesville, FL, USA.
Roniel CabreraDivision of Gastroenterology, Hepatology and Nutrition, University of Florida, 1600 SW Archer Rd, Gainesville, FL, USA.
University of Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMany patients are not candidates for liver transplant for non-tumor-related reasons including medical comorbidities and non-adherence. The prognosis of patients with hepatocellular carcinoma (HCC) who are not liver transplant candidates in the era of locoregional therapy (LRT) including y90 is not well defined.

aimsThis study seeks to evaluate outcomes and the natural history of early-stage HCC in patients who were denied liver transplant listing due to non-tumor reasons and instead were treated with LRT.

methodsA retrospective evaluation was performed for all patients who completed liver transplant evaluation with their tumor within Milan criteria but were denied due to non-tumor reasons and were treated with LRT at a single tertiary referral center.

resultsThe 61 patients included had a favorable overall survival, with a median survival 60.3 months (86.9% at 1 year and 52.7% at 5 years). Patients with Child-Pugh A cirrhosis (n = 34) had significantly longer overall survival compared to those with Child-Pugh B/C cirrhosis (median survival of 70.3 months versus 26.1 months, p = 0.005). Survival in patients with Child-Pugh A at 1, 3, and 5 years was 97%, 80%, and 73%, respectively, compared to 74%, 41%, and 31% in patients with Child-Pugh B/C.

conclusionsIn a small single-center cohort, patients with HCC who were denied liver transplant due to non-tumor reasons and underwent LRT and had Child-Pugh A cirrhosis had survival approaching the national average for patients who undergo liver transplantation. Patients with Child-Pugh B/C cirrhosis had significantly worse outcomes than those with Child-Pugh A.

Indexed as

Liver TransplantationAgedCarcinoma, HepatocellularCohort StudiesFemaleHumansLiver NeoplasmsMaleMiddle AgedNeoplasm StagingRetrospective StudiesSurvival RateTreatment OutcomeGastroenterologyHepatocellular carcinomaInterventional radiologyLiver cirrhosisLiver transplantation

Identifiers

PMID32219612
OpenAlexW3013177356

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.